Autoimmune Disease Treatment Market Research Report By Therapy Type (Biologics, Corticosteroids, Immunosuppressants, Small Molecule Drugs), By Disease Type (Rheumatoid Arthritis, Multiple Sclerosis, Lupus, Psoriasis, Inflammatory Bowel Disease), By Route of Administration (Oral, Injectable, Topical), By End-user (Hospitals, Clinics, Homecare Settings), and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035

Autoimmune Disease Treatment Market Summary

As per MRFR Analysis, the Autoimmune Disease Treatment Market was valued at 70.97 USD Billion in 2023 and is projected to grow to 100.5 USD Billion by 2035, with a CAGR of 2.94% from 2025 to 2035. The market is driven by the rising incidence of autoimmune diseases, advancements in therapeutic solutions, and increased healthcare expenditure.

Key Market Trends & Highlights

Key trends driving the Autoimmune Disease Treatment Market include advancements in treatment methodologies and increased patient awareness.

• The market for biologics is expected to reach over 46 billion USD by 2025.
• Biologics dominated the therapy type segment with a value of 25.0 USD Billion in 2024, projected to rise to 35.0 USD Billion by 2035.
• Rheumatoid Arthritis represents a major portion of the treatment market, necessitating ongoing therapy.
• North America held the largest market share at 32.0 USD Billion in 2024, expected to grow to 43.0 USD Billion by 2035.

Market Size & Forecast

2023 Market Size: USD 70.97 Billion

2024 Market Size: USD 73.05 Billion

2035 Market Size: USD 100.5 Billion

CAGR (2025-2035): 2.94%

Largest Regional Market Share in 2024: North America

Major Players

Merck and Co, Pfizer, AbbVie, Roche, Gilead Sciences, Johnson and Johnson, Eli Lilly, UCB, Novartis, Celgene, Bristol-Myers Squibb, Teva Pharmaceutical, AstraZeneca, Amgen, Sanofi

Key Autoimmune Disease Treatment Market Trends Highlighted

Numerous market factors are causing notable shifts in the global market for the treatment of autoimmune diseases. One major factor is the growing incidence of autoimmune illnesses worldwide, which raises the need for efficient therapies. As a result of increased awareness of these illnesses, governments and healthcare institutions are investing more funds in research and development.The industry is also being driven by the increased prevalence of autoimmune illnesses brought on by the world's aging population. Advances in tailored medicine and biotechnology are capturing opportunities in this industry.

More attention is being paid to creating customized treatments that target certain disease pathways in order to maximize therapeutic effectiveness and reduce adverse effects. Additionally, the partnership between research institutes and pharmaceutical firms is opening the door for novel treatments, such as biologics and monoclonal antibodies, which hold promise for treating complicated autoimmune diseases.

Through collaboration, stakeholders may optimize their research and development capacities and expedite the launch of novel medicines. Novel drug delivery technologies and immunotherapies are becoming more popular, according to recent developments in the global market for the treatment of autoimmune diseases.

Clinical trials for novel therapeutics have increased as a result of patients' growing need for safer and more efficient treatment choices. Additionally, the incorporation of digital health technologies, including telemedicine and mobile health apps, is enhancing patient monitoring and participation, which is revolutionizing the way treatments are delivered.This digital transformation is a significant trend in the present environment since it is improving compliance and giving patients more access to care.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Autoimmune Disease Treatment Market Drivers

Increasing Prevalence of Autoimmune Diseases Worldwide

The Autoimmune Disease Treatment Market is significantly driven by the rising prevalence of autoimmune diseases globally. According to the World Health Organization, autoimmune diseases affect approximately 5-8% of the global population, translating to millions of individuals suffering from these disorders.The common conditions include rheumatoid arthritis, lupus, and multiple sclerosis, which have shown increased incidence rates over the past decade.

Many established organizations, such as the American Autoimmune Related Diseases Association, have highlighted that autoimmune diseases are on the rise, potentially doubling in prevalence within the next 10 years, primarily due to environmental factors and genetic predispositions.This rising prevalence not only intensifies the demand for effective treatment options but also encourages investment in Research and Development (R&D) for new therapies, contributing positively to the growth prospects of the Autoimmune Disease Treatment Market.

Advancements in Biologic Therapies

Advancements in biologic therapies represent a crucial driver for the Autoimmune Disease Treatment Market. Biologics have transformed the treatment paradigms for several autoimmune diseases, offering targeted intervention rather than traditional broad-spectrum therapies.

The National Institute of Health reports a significant increase in the number of FDA-approved biologic therapies over the past decade, with figures indicating a 50% rise in approvals from 2010 to 2020.

These innovative treatment options, spearheaded by leading pharmaceutical firms like Amgen and AbbVie, are setting new standards in efficacy and safety for patients. As these therapies continue to evolve, they are expected to bolster market growth, catering to the increasing unmet needs in the autoimmune disease sector.

Growing Awareness and Understanding of Autoimmune Diseases

The growing awareness of autoimmune diseases plays a fundamental role in propelling the Autoimmune Disease Treatment Market forward. As public understanding improves, more individuals are encouraged to seek diagnoses and treatments for autoimmune conditions.Campaigns led by organizations such as the Autoimmune Advocacy Alliance have been effective in educating the population about these diseases, consequently leading to an increase in reported cases.

A survey conducted by the National Health Service revealed that approximately 75% of participants reported heightened awareness of autoimmune diseases over the past five years. This rising awareness not only contributes to early diagnosis but encourages patients to pursue available therapy options, significantly increasing the demand within the market.

Increased Investment in Research and Development

There is an increased investment in Research and Development (R&D) concerning autoimmune disease treatments that play a vital role in driving growth in the Autoimmune Disease Treatment Market. The global healthcare expenditure on R&D has shown an upward trend, with many governments and private sectors prioritizing funding for innovative treatments.

According to reports by the European Commission, total R&D investment in biomedical sectors reached 40 billion Euros in the past year, reflecting a commitment to advancing knowledge and therapy options for complex conditions like autoimmune diseases.Major pharmaceutical companies such as Johnson & Johnson and Novartis are at the forefront, investing billions into developing new drug formulas, which not only enhance treatment outcomes but also catalyze growth in the Autoimmune Disease Treatment Market.

Autoimmune Disease Treatment Market Segment Insights

Autoimmune Disease Treatment Market Therapy Type Insights

The Autoimmune Disease Treatment Market, particularly focusing on Therapy Type, showed a structured segmentation that highlights the importance of various treatment modalities in addressing autoimmune disorders.Among the treatment types, Biologics commanded a majority holding, valued at 30.0 USD Billion in 2024 and projected to advance to 40.0 USD Billion by 2035. The significance of Biologics lies in their targeted action and efficacy in managing severe autoimmune conditions, making them a forefront choice for practitioners.

Corticosteroids, with a 2024 valuation of 15.0 USD Billion, also played an essential role, especially due to their quick-acting anti-inflammatory properties, and are expected to expand to 20.0 USD Billion by 2035.Immunosuppressants, holding a valuation of 10.0 USD Billion in 2024, were crucial as they aided in preventing organ rejection in patients undergoing treatments such as organ transplants; they were anticipated to grow to 15.0 USD Billion by 2035.

Lastly, Small Molecule Drugs represented a noteworthy niche in the market with a value of 18.05 USD Billion in 2024, projected to reach 25.5 USD Billion by 2035. These drugs were pivotal in providing patients with more accessible administration routes and often came with fewer side effects compared to other treatment forms.

This diverse range of therapies within the Autoimmune Disease Treatment Market facilitated an effective response to the challenges posed by autoimmune diseases and highlights the innovative advancements in the field of medicine.The market growth is further driven by increasing global prevalence of autoimmune diseases, the continuous emergence of new therapies, and ongoing Research and Development investments to create more effective and safer treatment options tailored to individual patient needs.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Autoimmune Disease Treatment Market Disease Type Insights

The Autoimmune Disease Treatment Market, segmented by Disease Type, encompasses a variety of conditions such as Rheumatoid Arthritis, Multiple Sclerosis, Lupus, Psoriasis, and Inflammatory Bowel Disease, which collectively contribute to a substantial portion of the market's overall revenue.

Rheumatoid Arthritis represents a significant proportion within this segment due to its prevalence, leading to an ongoing need for innovative therapies. Similarly, Multiple Sclerosis and Lupus are critical focus areas, with advancements in treatment methods driving market growth and improving patient quality of life.Psoriasis also poses significant challenges, as it impacts not only the skin but also mental health, highlighting the importance of holistic treatment approaches.

Inflammatory Bowel Disease, which includes conditions like Crohn's disease and ulcerative colitis, is gaining attention due to its increasing incidence globally. As the Autoimmune Disease Treatment Market continues to evolve, these segments play crucial roles in shaping treatment options and addressing the diverse needs of patients.

Autoimmune Disease Treatment Market Route of Administration Insights

The Autoimmune Disease Treatment Market has been significantly influenced by the Route of Administration segment, which comprises various methods such as Oral, Injectable, and Topical.The Oral route has gained popularity due to its ease of use and patient compliance, making it a vital aspect of the treatment landscape, particularly for chronic autoimmune conditions. Injectable therapies continue to dominate as they often provide rapid therapeutic effects, which is essential for many patients seeking immediate relief.

Topical applications are also noteworthy, especially for localized autoimmune conditions, allowing for focused treatment with minimal systemic exposure. The increasing prevalence of autoimmune diseases globally and the ongoing advancements in drug delivery systems contribute to the growth and evolution of this segment.

With a strong emphasis on patient-centric approaches and the rising adoption of biologics in the injectable category, the Route of Administration segment plays a crucial role in shaping the Autoimmune Disease Treatment Market dynamics. The market growth is further driven by an aging population, evolving treatment protocols, and heightened awareness surrounding autoimmune disorders.

Autoimmune Disease Treatment Market End-user Insights

The End-user segment is crucial in this market, with distinct roles played by various healthcare settings. Hospitals represent a significant portion of this market due to their advanced infrastructure and availability of specialized medical personnel, enabling comprehensive treatment for autoimmune diseases.

Clinics also play an essential role, often serving as the first point of contact for patients, facilitating timely diagnosis and management. Homecare settings are increasingly becoming a preferred option, especially for long-term management and support for patients, given the rising demand for personalized care.

The growing prevalence of autoimmune diseases, along with advancements in treatment strategies, drives the expansion of healthcare services within these segments. The demographic changes, particularly the aging population, contribute to the rising autoimmune disease incidence, creating further opportunities for market growth.

Overall, the Autoimmune Disease Treatment Market segmentation highlights the importance of tailored approaches in addressing the unique needs of patients across different environments, ultimately enhancing the efficacy and convenience of treatment.

Autoimmune Disease Treatment Market Regional Insights

The Autoimmune Disease Treatment Market witnessed substantial growth on a regional scale, with North America leading the way.In 2024, North America was valued at 35.5 USD Billion, which is a significant majority holding in the market. This region was home to advanced healthcare infrastructure and robust Research and Development initiatives, making it pivotal in driving innovation in autoimmune disease treatments.

Europe followed closely with a valuation of 22.0 USD Billion in the same year, reflecting its strong emphasis on healthcare policies and increasing disease awareness among its population. South America, while smaller with a valuation of 3.5 USD Billion, presented opportunities for growth due to improving healthcare access and the rising incidence of autoimmune disorders.

The Asia Pacific region, valued at 9.0 USD Billion, is emerging as a vital market due to its large population and expanding healthcare capabilities. Although the Middle East and Africa held a lower valuation of 3.05 USD Billion, they were important regions as they gradually increased healthcare investments, thereby improving diagnostics and treatments available for autoimmune diseases.

Overall, the diverse dynamics across these regions illustrated the varying levels of market development and opportunities within the Autoimmune Disease Treatment Market.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Autoimmune Disease Treatment Market Key Players and Competitive Insights

The Autoimmune Disease Treatment Market has seen significant growth due to the increasing prevalence of autoimmune disorders, a greater awareness of these diseases, and advancements in treatment options. Market dynamics are driven by the need for innovative therapies, the rising patient population, and ongoing research into various autoimmune conditions.The competitive landscape features a blend of established pharmaceutical giants and emerging biotech firms, each striving to develop treatments that can effectively manage or potentially cure these complex diseases.

A variety of treatment types, including biologics, corticosteroids, and immunosuppressants, are available, which enhances competition among companies. Companies are focusing on research and development to innovate new medication and solutions that cater to diverse patient needs across different regions.Novartis has a strong foothold in the Autoimmune Disease Treatment Market, characterized by innovative therapeutic offerings and a commitment to research. The company is well-known for its robust pipeline, featuring multiple drug candidates that target various autoimmune conditions.

As a leader in specialty pharmaceuticals, Novartis stands out due to its investment in developing biologics and targeted therapies that address diseases such as rheumatoid arthritis and psoriasis. Its comprehensive approach combines effective treatments with patient support services, enhancing overall patient experience.The company also leverages strategic partnerships and collaborations to broaden its research capabilities, significantly contributing to its presence in the global market for autoimmune diseases.

Regeneron Pharmaceuticals is recognized for its innovative therapies in the Autoimmune Disease Treatment Market, gaining attention for its unique drug offerings like monoclonal antibodies that are designed to treat conditions such as moderate to severe eczema and other autoimmune diseases.

The company has cultivated a solid market presence through a combination of groundbreaking research, strategic partnerships, and a strong commitment to delivering high-quality products. Regeneron has made notable advancements through mergers and acquisitions, positioning itself as a key player in the industry.

Its approach emphasizes not only drug development but also a focus on patient access and education programs, further enhancing its strengths in this market. The company continues to explore new indications for its existing products, reinforcing its competitive edge globally in the autoimmune disease treatment sector.

Key Companies in the Autoimmune Disease Treatment Market Include

• Novartis


• Regeneron Pharmaceuticals


• Pfizer


• Gilead Sciences


• Celgene


• Merck & Co


• Amgen


• AstraZeneca


• Eli Lilly


• Teva Pharmaceuticals


• Sanofi


• Johnson & Johnson


• Roche


• BristolMyers Squibb


• AbbVie

Autoimmune Disease Treatment Market Developments

Celltrion expanded their autoimmune portfolio to include IL-6 inhibitors in addition to TNF-α biosimilars on February 25, 2025, when the European Commission approved Avtozma, a biosimilar of Actemra (tocilizumab).With an 87 percent decrease in flare risk, Amgen's Uplizna (inebilizumab) was authorized by the U.S. Food and Drug Administration on April 3, 2025, making it the first licensed treatment for IgG4-related illness.In order to improve patient access and move Medicare coverage to Part D, Argenx acquired FDA approval on April 11, 2025, for the at-home self-administration of Vyvgart Hytrulo in CIDP and generalized myasthenia gravis.

The promise of "inverse vaccines," which use antigen-laden nanoparticles to retrain immune responses in diseases like multiple sclerosis and celiac disease, was emphasized by biotech leaders on May 14, 2025. It is anticipated that this method will enter more extensive human trials in three to ten years.AbbVie strengthened its pipeline when the Humira patent expired on June 30, 2025, when it agreed to pay up to $2.1 billion to purchase CAR-T specialist Capstan Therapeutics, which develops CPTX2309 for autoimmune illnesses.

According to study reports, Pfizer Korea introduced Litfulo (ritlecitinib tosylate), a JAK inhibitor, for the treatment of severe alopecia areata on June 27, 2025. A mid-2025 update on CRISPR Therapeutics' allogeneic CAR-T treatment CTX112 for SLE and other autoimmune illnesses is also planned.

Autoimmune Disease Treatment Market Segmentation Insights

Autoimmune Disease Treatment Market Therapy Type Outlook

• Biologics


• Corticosteroids


• Immunosuppressants


• Small Molecule Drugs

Autoimmune Disease Treatment Market Disease Type Outlook

• Rheumatoid Arthritis


• Multiple Sclerosis


• Lupus


• Psoriasis


• Inflammatory Bowel Disease

Autoimmune Disease Treatment Market Route of Administration Outlook

• Oral


• Injectable


• Topical

Autoimmune Disease Treatment Market End-user Outlook

• Hospitals


• Clinics


• Homecare Settings

Autoimmune Disease Treatment Market Regional Outlook

• North America


• Europe


• South America


• Asia Pacific


• Middle East and Africa

Report Attribute/Metric	Details
Market Size 2023	70.97(USD Billion)
Market Size 2024	73.05(USD Billion)
Market Size 2035	100.5(USD Billion)
Compound Annual Growth Rate (CAGR)	2.94% (2025 - 2035)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Novartis, Regeneron Pharmaceuticals, Pfizer, Gilead Sciences, Celgene, Merck & Co, Amgen, AstraZeneca, Eli Lilly, Teva Pharmaceuticals, Sanofi, Johnson & Johnson, Roche, BristolMyers Squibb, AbbVie
Segments Covered	Therapy Type, Disease Type, Route of Administration, End-user, Regional
Key Market Opportunities	Biologics and biosimilars expansion, Personalized medicine advancements, Increased prevalence awareness, Novel drug development pipelines, Digital health integration solutions
Key Market Dynamics	Rising prevalence of autoimmune diseases, Increasing demand for biological therapies, Advancements in personalized medicine, Growing patient awareness and education, Strong pipeline of innovative treatments
Countries Covered	North America, Europe, APAC, South America, MEA